Look back at pharma news to Mar 17

19 March 2017

Barbara Obstoj-Cardwell. Editor

Among the political news last week, perhaps the most controversial of which was US President Donald Trump’s budget blueprint – a wish list of spending priorities for legislators to consider, which included a proposal to double the use fee charge that drugmakers pay to get their products through the regulatory process and a much criticized 20% cut in the budget for the National Institutes of Health.

Also big on the news agenda was one of the biggest stake holders in Valeant Pharmaceuticals International pulling out at a substantial loss; anther approval for Merck & Co’s Keytruda; the first approval for Novartis’ CDK4/6 inhibitor Kisqali; Strong Repatha trial results that still disappointed; and better-than-expected new data on AstraZeneca’s Lynparza.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK